Johnson & Johnson JNJ is trading higher Tuesday after the company announced better-than-expected third-quarter earnings results and raised guidance.
Johnson & Johnson reported quarterly adjusted earnings of $2.60 per share, which beat the estimate of $2.36 per share. The company reported quarterly revenue of $23.34 billion, which came in below the estimate of $23.74 billion.
Johnson & Johnson raised its full-year 2021 earnings guidance from a range of $9.60 to $9.70 per share to a range of $9.77 to $9.82 per share versus the estimate of $9.66 per share.
The company raised its full-year 2021 revenue guidance from a range of $93.8 billion to $94.6 billion to a range of $94.1 billion to $94.6 billion versus the estimate of $94.3 billion.
"Our third-quarter results demonstrate solid performance across Johnson & Johnson, driven by robust above-market results in Pharmaceuticals, ongoing recovery in Medical Devices, and strong growth in Consumer Health," said Alex Gorsky, chairman and CEO of Johnson & Johnson.
JNJ Price Action: Johnson & Johnson has traded as high as $179.92 and as low as $133.65 over a 52-week period.
The stock was up 2.83% at $164.65 at time of publication.
Photo: Public Domain from Flickr.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.